BioSpace News Archive

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, intends to report operational highlights and financial results for the year ended December 31, 2020 on Thursday, March 4, 2021

Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing

We are very impressed by our employees and partners for their resilience and achievements during 2020.

Durable responses observed with COM701 in combination with Opdivo® including a confirmed complete response in a patient with prior progression on Opdivo®

Miroculus, Inc., a developer of revolutionary tools for personal lab automation, today announced the completion of a Series B extension, bringing the total capital raised in the series to $45M.

CTP-543 Phase 3 Program Advancing in Alopecia Areata; THRIVE-AA2, the Second CTP‑543 Phase 3 Trial, to Initiate 1H2021 CTP-543 Long-Term Data Presented at EADV Show Hair Regrowth was Maintained or Improved in Patients with Alopecia Areata, Expanding Previous Phase 2 Results Conference Call and Webcast Scheduled Today at 8:30 a.m. ET

ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve patient access, safety and convenience. As well, James (Jim) Sherblom has joined the board of directors of ReForm as chairman to lead the shift in strategy.

— Achieved Favorable Clinical Results Across Four First-in-Class Gene Therapy Programs for Danon Disease, FA, LAD-I and PKD — — Announced >50% Protein Expression with Stabilization and Biomarker Improvement Including Cardiac Output in Low Dose Cohort for Danon Disease Heart Failure Program —

EUSA Pharma (UK) Limited (“EUSA Pharma”), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network® (NCCN®) has updated their Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas to include siltuximab (SYLVANT®)

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) , a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo Adversa and QIXLEEF in Denmark, Norway, Sweden, Finland, and Germany.